GlobalData05.24.17
The total knee replacement market in North America, which covers Canada, Mexico, and the United States, is set to rise from $3.63 billion in 2016 to around $4.2 billion by 2023, representing a compound annual growth rate of 2.2 percent, according to research and consulting firm GlobalData.
The company’s latest report states that this modest growth will be driven by the growing prevalence of osteoarthritis, continued technological advancements in joint reconstruction surgeries, healthcare reform and a focus on economical modes of treatment.
“There are multiple paths that the total knee replacement market could take as it develops. For example, investments could be made into expensive capital equipment such as robots, which will result in consistent, reproducible implant placement, less soft tissue damage, and shorter rehabilitation periods. This would lead to lower post-surgical costs," explained Tobe Madu, MSc, healthcare analyst for GlobalData. “Additionally, there is a case to be made for custom implants leading to fewer complications and potentially reducing post-acute care costs. Further research will have to be carried out on the economics of each scenario and its ability to scale, and each specific geographical region will require a different approach."
Knee reconstruction is a fully mature market that has experienced no major innovation over the last decade other than incremental improvements. As health executives are scrutinizing purchases and using multiple channels to procure orthopedic devices at highly competitive prices, profit margins have been negatively affected, with global revenues falling in the large joint reconstruction space.
“A long-term foothold within the North American knee market hinges on how well companies can align themselves with the primary market force buffeting healthcare today: the need to deliver top-notch, cost-effective care," Madu continued. “North America accounts for approximately 50 percent of the global knee reconstruction market therefore, given the heightened competitive pressures and shrinking reimbursement globally, the average selling price for total knee reconstruction implants is expected to decline. However, GlobalData believes that the revenue from increased procedure volume will make up for this loss.”
Roughly 4,000 of the world’s largest companies, including more than 70 percent of FTSE 100 and 60 percent of Fortune 100 companies, make more timely and better business decisions thanks to GlobalData’s data, expert analysis and innovative solutions. GlobalData provides market research across a range of industries, including the healthcare, consumer, retail, financial, technology and professional services sectors.
The company’s latest report states that this modest growth will be driven by the growing prevalence of osteoarthritis, continued technological advancements in joint reconstruction surgeries, healthcare reform and a focus on economical modes of treatment.
“There are multiple paths that the total knee replacement market could take as it develops. For example, investments could be made into expensive capital equipment such as robots, which will result in consistent, reproducible implant placement, less soft tissue damage, and shorter rehabilitation periods. This would lead to lower post-surgical costs," explained Tobe Madu, MSc, healthcare analyst for GlobalData. “Additionally, there is a case to be made for custom implants leading to fewer complications and potentially reducing post-acute care costs. Further research will have to be carried out on the economics of each scenario and its ability to scale, and each specific geographical region will require a different approach."
Knee reconstruction is a fully mature market that has experienced no major innovation over the last decade other than incremental improvements. As health executives are scrutinizing purchases and using multiple channels to procure orthopedic devices at highly competitive prices, profit margins have been negatively affected, with global revenues falling in the large joint reconstruction space.
“A long-term foothold within the North American knee market hinges on how well companies can align themselves with the primary market force buffeting healthcare today: the need to deliver top-notch, cost-effective care," Madu continued. “North America accounts for approximately 50 percent of the global knee reconstruction market therefore, given the heightened competitive pressures and shrinking reimbursement globally, the average selling price for total knee reconstruction implants is expected to decline. However, GlobalData believes that the revenue from increased procedure volume will make up for this loss.”
Roughly 4,000 of the world’s largest companies, including more than 70 percent of FTSE 100 and 60 percent of Fortune 100 companies, make more timely and better business decisions thanks to GlobalData’s data, expert analysis and innovative solutions. GlobalData provides market research across a range of industries, including the healthcare, consumer, retail, financial, technology and professional services sectors.